HOME > TOP STORIES
TOP STORIES
-
COMMENTARY Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
-
ORGANIZATION FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
-
ORGANIZATION Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
-
ORGANIZATION Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
-
REGULATORY Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
-
REGULATORY Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
-
REGULATORY Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
-
REGULATORY MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
-
REGULATORY Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
-
REGULATORY Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
-
BUSINESS Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
-
REGULATORY Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
-
TRENDS Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
-
REGULATORY LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
-
REGULATORY LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
-
BUSINESS Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
-
REGULATORY LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
-
BUSINESS AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
-
ORGANIZATION Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
-
BUSINESS Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
